title: Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
authors.affiliation: Medical Department, Pfizer Australia, Sydney, New South Wales, Australia.
authors.forename: G C
authors.initials: GC
authors.lastname: Fenn
authors.forename: M
authors.initials: M
authors.lastname: Grobler
authors.forename: D
authors.initials: D
authors.lastname: Schaffer
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D016861:Cyclooxygenase Inhibitors / Q000191:economics / Q000627:therapeutic use*; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D006801:Humans; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D012216:Rheumatic Diseases / Q000188:drug therapy* / Q000201:enzymology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D016861:Cyclooxygenase Inhibitors